6.21
Insuficiencia renal: ajustes de dosis
En pacientes con insuficiencia renal, los fármacos sufren cambios significativos en su farmacocinética, que requieren ajustes de dosis para garantizar…
En los pacientes con insuficiencia renal, los fármacos presentan una farmacocinética alterada.
La reducción del aclaramiento renal y la tasa de eliminación dan como resultado una vida media de eliminación prolongada, lo que requiere ajustes de dosis.
No es necesario cambiar la pauta posológica cuando la fracción del fármaco excretado sin cambios es ≤ 0,3 y la función renal, FR, es ≥ 0,7 de lo normal.
Esta suposición se basa en la inactividad de los metabolitos, las características de unión inalteradas y la disponibilidad sostenida del fármaco durante la insuficiencia renal.
Sin embargo, a medida que fu se acerca a la unidad y la RF se acerca a cero, la eliminación se ralentiza significativamente, lo que requiere una reducción sustancial de la dosis.
El aclaramiento no renal gana prominencia en estas condiciones.
Una simple ecuación calcula la dosis requerida en pacientes con insuficiencia renal.
Del mismo modo, se puede calcular el intervalo de dosificación.
Los ajustes de dosis suelen ser necesarios para fármacos con índices terapéuticos bajos.
View the full transcript and gain access to JoVE Core videos
Q1: When do patients with renal impairment not need dose adjustments?
Dosage adjustments are unnecessary when the fraction of drug excreted unchanged (fu) is ≤ 0.3 and renal function (RF) is ≥ 0.7 of normal. This assumes metabolites remain inactive, protein-binding characteristics stay unchanged, and drug availability is sustained during renal failure. Under these conditions, renal clearance reduction does not significantly impact drug elimination.
Q2: How does renal impairment change drug elimination half-life?
Renal impairment reduces renal clearance and elimination rate, prolonging the drug's elimination half-life. This extended half-life means the drug remains in the body longer, increasing the risk of accumulation. Prolonged half-life is a key reason why dose adjustments become necessary in patients with compromised renal function.
Q3: What role does nonrenal clearance play when kidney function declines?
As renal clearance decreases, nonrenal clearance—including hepatic metabolism and other elimination pathways—gains prominence in removing drugs from the body. Understanding the interplay between renal and nonrenal clearance is crucial for determining appropriate dosage adjustments. When fu approaches unity and renal function nears zero, nonrenal routes become the primary elimination mechanism.
Q4: Why do drugs with high fraction excreted unchanged require substantial dose reduction?
Drugs with fu approaching unity are eliminated primarily through the kidneys. As renal function declines toward zero, elimination slows significantly, causing drug accumulation and potential toxicity. Substantial dose reduction is necessary to prevent toxic levels while maintaining therapeutic effectiveness in patients with severe renal impairment.
Q5: Which drugs require the most careful dose adjustment in renal failure?
Drugs with low therapeutic indices require the most careful dose adjustments in renal failure. These drugs have a narrow margin between therapeutic and toxic doses, making it critical to maintain drug levels within the therapeutic range. Even small accumulations from reduced renal clearance can cause toxicity in patients with renal impairment.
Q6: How can clinicians calculate appropriate doses for renally impaired patients?
A simple equation calculates the required dose in patients with renal impairment by accounting for changes in drug clearance. Similarly, the dosing interval can be computed based on the drug's half-life and desired drug concentrations. These calculations ensure optimal drug levels while preventing accumulation and toxicity.
Q7: What assumptions must hold for drugs with low renal excretion to avoid dose adjustment?
For drugs with fu ≤ 0.3 to avoid dose adjustment despite renal impairment, three assumptions must hold: drug metabolites must be inactive, protein-binding characteristics must remain unchanged, and drug availability must be sustained during renal failure. If any assumption fails, dose adjustments become necessary even for drugs with low renal excretion.